The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) reports 2020 data and 2021 features of the Maryland state Prescription Drug Monitoring Program (PDMP).
The name of the Maryland PDMP is Prescription Drug Monitoring Program (PDMP), and it is administered by the Maryland Department of Health, Office of Provider Engagement and Regulation. The email address is provided, along with URLs for the main PDMP website and related websites for enrollment, query, and data upload. Contact information is provided for the PDMP Assistant Director and the Deputy Director. In 2020, the state population of Maryland was 6,185,278, and there were 39,722 DEA-registered prescribers and 1,313 DEA-registered dispensers. A total of 20 reports and their topics are listed as being produced and available from the PDMP. PDMP sources of funding for 2021 are the state general fund, a BJA grant, and a CDC grant. Four PDMP staff members perform operational tasks and three employees perform tasks related to PDMP analytical/epidemiological responsibilities. Key dates are reported for events in the establishment and development of the PDMP. Information is also provided for accessing statutes and rules relevant to the establishment and policies of the PDMP. Fifteen miscellaneous capabilities and policies of the PDMP are listed. The PDMP has a data retention policy. Training in the features and uses of the PDMP is available for prescribers, dispensers, law enforcement personnel, the regulatory board, and the Attorney General, and training if required before PDMP use by prescribers, dispensers, law enforcement, the regulatory board, and the Attorney General. Law enforcement personnel must have a subpoena to access information on patients and drug prescriptions. Enrollment in PDMP and its use is required for prescribers and dispensers. Veterinarians are required to enroll with the PDMP as data requesters. The data that are monitored or accessible pertain to substances listed in Schedules II-V. Data are collected on fatal and non-fatal overdoses, and substance use trends are monitored to inform policy.